A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

NCT07231952 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Waldenstrom Macroglobulinemia
Lymphoplasmacytic Lymphoma

Interventions

DRUG: Pirtobrutinib
DRUG: Venetoclax
DRUG: Rituximab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]